Jennifer Johnston, PhD, Chairs First CNS Degrader Meeting on Oct 30th in Boston

Written By Kim Markworth
 
 

San Francisco | October 20, 2023

Dr. Jennifer Johnston’s team has been working on the identification of small molecule modulators of the E3 ubiquitin ligase, Parkin, for the last 18 years. On Monday, October 30, 2023, she will discuss momentum in tackling the challenges for advancement of degrader molecules for CNS disorders. Ahead of the conference, she was interviewed about her involvement in the TPD field: read the interview here.


For conference registration and more information, visit:
https://proteindegradation.com/take-part/register/

For more information on FinsnoBio, and innovations in Parkin therapeutics, contact us at info@finsnobio.com



Kim Markworth

CEO / Creative Director

Markworth Creative Advertising & Design

Since 1998

https://markworthcreative.com
Next

FinsnoBio and Accelero Biostructures Announce Partnership for X-Ray Crystallography Drug Discovery